I’m at the Mayo as I write and part of the trial that went to open label three month ago. In Dec of 2023 I was at Mayo stage 4 still here thinking the drug has benefited me and hopefully others.

Don't forget about Prothena's Birtamimab trial (formerly known as NEOD001). It is hoped that this drug will remove existing amyloid deposits from the body.

Don, yes, depleter drug trials are ongoing. There are 4 different depleter drug trials. The drugs do not "reverse" amyloid deposits. Three are monoclonal antibody type of infusion drugs that make the insoluble amyloid fibrils soluble (they target only the amyloids in the heart) and therefore, excretable. One is Alexion ALXN2220, another is a Novo Nordisk drug, Amitug (NNC6019-0001). It differs from all of the others.
It's designed to break down TTR amyloid deposits and prevent new amyloid from forming. The 3rd depleter drug is one I don't recall.

The 4th one, Attralus AT-02, is a humanized IgG1 monoclonal antibody that is genetically fused with the company's pan-amyloid binding peptide, that enables it to bind to multiple types of amyloid deposits. The AT-02 antibody stimulates the immune system to remove amyloid deposits that are bound by the AT-02. It basically uses macrophages and other immune system "warriors" to surround and then absorb and breakdown amyloid deposits everywhere and anywhere they are in the body.

Yes. Jury’s still out on CAEL-101. The current Phase 3 trial on Mayo IIIa patients is supposed to be completed in the next couple months. From what I’ve seen and heard, skepticism about its efficacy prevails. But, 🤞